Advanced search
Start date
Betweenand


Polymersomes for protein drug delivery across intestinal mucosa

Full text
Author(s):
Muso-Cachumba, Jorge Javier ; Feng, Sa ; Belaid, Mona ; Zhang, Yunyue ; Rangel-Yagui, Carlota de Oliveira ; Vllasaliu, Driton
Total Authors: 6
Document type: Journal article
Source: International Journal of Pharmaceutics; v. 648, p. 9-pg., 2023-11-19.
Abstract

The oral administration is the route preferred by patients due to its multiple advantages. In the case of bio-pharmaceuticals, due to their low stability and absorption in the intestine, these molecules must be administered by injectable routes. To circumvent these problems, several strategies have been studied, among which the use of nanosystems, such as polymersomes, can be highlighted. In this work the potential of poloxamer 401 polymersomes as a system for oral delivery of antibodies was evaluated. IgG-FITC-loaded poloxamer 401 polymer-osomes were initially used to assess whether it improves intestinal epithelial permeation in Caco-2 cell monolayers. Subsequently, epithelial/macrophage co-culture model was used to evaluate the ability of polox-amer 401 polymersomes containing adalimumab to reduce proinflammatory cytokine levels. The data showed that polymersome-encapsulated IgG increased the transport across intestinal Caco-2 monolayers 2.7-fold compared to the antibody in solution. Also, when comparing the groups of blank polymersomes with polymersomes containing adalimumab, decreases of 1.5-, 5.5-, and 2.4-fold in TNF-alpha concentrations were observed for the polymersomes containing 1.5, 3.75, and 15 mu g/mL of adalimumab, respectively. This could indicate a possibility for the oral administration of biopharmaceuticals which would revolutionize many conditions that require the systemic administration such as in inflammatory bowel disease. (AU)

FAPESP's process: 20/08129-6 - Evaluation of free and nanostructured enzymes for cutaneous anti-aging effect and photoprotection
Grantee:Carlota de Oliveira Rangel Yagui
Support Opportunities: Regular Research Grants
FAPESP's process: 22/02456-0 - Preclinical in vivo assays to evaluate asparaginase biobetters
Grantee:Gisele Monteiro
Support Opportunities: Regular Research Grants